A Prospective Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma

University of Michigan Rogel Cancer Center1 site in 1 country6 target enrollmentJuly 5, 2018

ConditionsGlioblastoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Glioblastoma
Sponsor: University of Michigan Rogel Cancer Center
Enrollment: 6
Locations: 1
Primary Endpoint: Identify candidate genes with differential expression in therapy-resistant imaging subvolumes
Status: Terminated
Last Updated: 10 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be non-invasively identified using imaging phenotypes that identify regionally distinct areas of tumor with genetic alterations that drive tumor resistance pathways. The researchers propose a unique approach to assess initial GBM heterogeneity by performing histological and genomic analysis of biopsies targeted by advanced MRI before treatment.

Registry

clinicaltrials.gov

Start Date

July 5, 2018

End Date

March 23, 2020

Last Updated

10 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University of Michigan Rogel Cancer Center

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Suspected newly diagnosed or recurrent supratentorial glioblastoma eligible for surgical biopsy and/or resection
•Patients must be 18 years of age or older
•Study-specific informed consent approved for this purpose by the IRB of the University of Michigan